Aptorum Group Limited logo
Aptorum Group Limited APM
$ 0.93 -8.82%

Annual report 2024
added 03-21-2026

report update icon

Aptorum Group Limited EPS Ratio 2011-2026 | APM

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Aptorum Group Limited

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-0.78 -0.62 -2.75 -7.15 0.2 -0.64 -0.53 -0.09 - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
0.2 -7.15 -1.55

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-15.4 - 2.43 % $ 254 M germanyGermany
Verastem Verastem
VSTM
-3.02 $ 5.04 -4.73 % $ 349 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
-1.67 $ 0.57 -5.87 % $ 17.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-3.75 - - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
-7.66 - - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
1.51 - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-0.26 - -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
-1.96 - 10.36 % $ 9.8 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-31 - -18.52 % $ 27.3 M britainBritain
Aptinyx Aptinyx
APTX
-0.96 - -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-15.8 - -52.27 % $ 4.45 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
-0.39 $ 12.41 -11.1 % $ 1.88 B usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
-3.01 $ 54.48 -1.89 % $ 4.24 B canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
0.2 - 0.49 % $ 251 B cayman-islandsCayman-islands
ChemoCentryx ChemoCentryx
CCXI
-1.89 - - $ 3.74 B usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
-1.08 - - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-2.21 - - $ 867 M germanyGermany
Summit Therapeutics Summit Therapeutics
SMMT
-1.44 $ 16.58 -3.94 % $ 12.4 B britainBritain
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-2.08 - -74.18 % $ 955 K usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
2.39 $ 317.36 -3.29 % $ 41.6 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-0.17 $ 4.29 -3.6 % $ 822 M canadaCanada
Allakos Allakos
ALLK
-2.14 - - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-1.06 - -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-0.72 - 3.16 % $ 1.9 M usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
-1.45 - - $ 1.41 B canadaCanada
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-10.7 - -11.43 % $ 502 K usaUSA
AlloVir AlloVir
ALVR
-2.85 - 4.14 % $ 49.1 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
2.1 $ 19.01 -2.66 % $ 889 M usaUSA
Gritstone Oncology Gritstone Oncology
GRTS
-1.2 - 0.42 % $ 213 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
1.37 $ 20.75 -3.35 % $ 3.44 B usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
-2.45 $ 6.66 -5.4 % $ 65.8 M usaUSA
Aravive Aravive
ARAV
-2.1 - -13.39 % $ 1.45 M usaUSA
Alkermes plc Alkermes plc
ALKS
1.47 $ 29.39 -1.77 % $ 4.84 B irlandaIrlanda
Cabaletta Bio Cabaletta Bio
CABA
-2.1 $ 2.68 -4.96 % $ 269 M usaUSA
AbbVie AbbVie
ABBV
1.02 $ 209.4 -0.81 % $ 370 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
-0.49 $ 3.27 -2.39 % $ 977 M canadaCanada
ARCA biopharma ARCA biopharma
ABIO
-3.87 - 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-1.66 - 2.71 % $ 14 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-204 - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-0.79 - 4.01 % $ 150 M canadaCanada
Athira Pharma Athira Pharma
ATHA
-2.52 - - $ 269 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-6.62 - - $ 86.2 M usaUSA